TAK
Takeda Pharmaceutical Company Limited · Healthcare · Drug Manufacturers - Specialty & Generic
动量输入（同类管理人）：
持有人广度 +16.7% ·
股份流向 -1.0% ·
净新建仓位 +14.3%
· 公式
持有人分散化：持有人数增多，合计持仓比例缩小。
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 64.36K | $1.19M | +1 | −1 |
| Q2 2026 | 86 | +7 | 88.63M | $1.46B | +9 | −3 |
| Q1 2026 | 81 | +2 | 81.32M | $1.54B | +7 | −5 |
| Q4 2025 | 79 | -2 | 68.50M | $1.10B | n/a | −2 |
| Q3 2025 | 14 | +2 | 31.18M | $456.42M | +3 | −1 |
| Q2 2025 | 9 | -3 | 18.36M | $283.88M | n/a | −3 |
| Q1 2025 | 9 | +1 | 8.73M | $129.81M | +2 | −1 |
| Q4 2024 | 8 | +3 | 9.62M | $127.30M | +4 | −1 |
| Q3 2024 | 5 | 0 | 11.53M | $98.50M | +1 | −1 |
| Q2 2024 | 5 | n/a | 10.02M | $129.64M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley ✦ | 7.69M | n/a | $112.59M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 2 | Goldman Sachs Group ✦ | 4.95M | n/a | $72.52M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 3 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 4 | Renaissance Technologies ✦ | 3.86M | +17.1% | $56.58M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 5 | BlackRock ✦ (被动) | 3.31M | -6.8% | $48.42M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | Arrowstreet Capital ✦ | 2.83M | +132.1% | $41.41M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | Millennium Management ✦ | 2.56M | -17.2% | $37.42M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 9 | JPMorgan Chase ✦ | 495.06K | n/a | $7.25M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 10 | D. E. Shaw & Co. ✦ | 281.29K | 新增 | $4.12M | 0.0% | New | 1 | SEC ↗ |
| 11 | The Vanguard Group ✦ (被动) | 101.87K | 0.0% | $1.49M | 0.0% | Held | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 75.62K | 新增 | $1.11M | 0.0% | New | 1 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 40.48K | -59.0% | $592,686 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Marshall Wace ✦ | 27.77K | 新增 | $406,494 | 0.0% | New | 1 | SEC ↗ ×2 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| D. E. Shaw & Co. | $4.12M | 0.0% |
| Citadel Advisors | $1.11M | 0.0% |
| Marshall Wace | $406,494 | 0.0% |
已清仓
| Adage Capital Partners | $39.17M | 曾为 0.1% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 356 持有人, 97.72M 股份, $1.74B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 34.53K 股 · $640,279
Officer, Director · 19.65K 股 · $363,347
Officer · 12.98K 股 · $235,118
Officer · 47.59K 股 · $813,721
Officer · 14.01K 股 · $239,503
Officer · 30.87K 股 · $527,843
Officer · 975 股 · $17,062
Officer · 33.63K 股 · $588,715
Officer · 6.77K 股 · $115,835
Officer · 50.01K 股 · $855,205
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论